Table 2.
Comparison of the Characteristics of Adult Diffuse Hemispheric Gliomas, H3 G34-Mutant with Those of H3.3 K27-mutant DMG, IDH1/2-mutant Glioblastomas and pTERT-mutant Glioblastomas
| H3.3 G34-mutant gliomas (n = 17) | H3.3 K27-mutant DMG (n = 33) | P a | IDH-mutant glioblastomas (n = 36) | P b | IDH-wt glioblastomas (n = 100) | P c | |
|---|---|---|---|---|---|---|---|
| Median age at diagnosis (years) | 25.8 (SD = 5.9) | 34.8 (SD = 16.5) | .005 | 38.5 (SD = 13.7) | <.001 | 66.4 (SD = 11.8) | <.001 |
| Sex | .30 | ||||||
| Male | 11/17 (65%) | 15/33 (45%) | .24 | 13/36 (36%) | .09 | 49/100 (49%) | |
| Female | 6/17 (35%) | 18/33 (55%) | 23/36 (64%) | 51/100 (51%) | |||
| Location | |||||||
| Frontal | 11/16 (69%) | 0/33 (0%) | <.001 | 24/36 (67%) | .99 | 48/100 (48%) | .27 |
| Parietal | 11/16 (69%) | 0/33 (0%) | <.001 | 7/36 (19%) | .001 | 22/100 (22%) | <.001 |
| Temporal | 3/16 (19%) | 2/33 (6%) | .31 | 11/36 (31%) | .51 | 32/100 (32%) | .25 |
| Occipital | 1/16 (6%) | 0/33 (0%) | .32 | 1/36 (3%) | .52 | 14/100 (14%) | .69 |
| Corpus callosum | 3/16 (19%) | 0/33 (0%) | .03 | 11/36 (31%) | .50 | 33/100 (33%) | .38 |
| Midline | 4/16 (25%) | 33/33 (100%) | <.001 | 10/36 (28%) | .99 | 10/100 (10%) | .11 |
| Initial hemorrhage | .01 | ||||||
| Yes | 3/16 (19%) | 0/33 (0%) | .03 | 2/36 (6%) | .16 | 2/100 (2%) | |
| No | 13/16 (81%) | 33/33 (100%) | 34/36 (94%) | 98/100 (98%) | |||
| Radiological features | |||||||
| CE | 4/15 (27%) | 18/29 (62%) | .05 | 27/36 (75%) | .002 | 93/100 (93%) | <.001 |
| Cyst | 2/16 (12%) | 3/28 (11%) | .60 | 7/36 (19%) | .70 | 8/100 (8%) | .60 |
| Necrosis | 1/16 (6%) | 10/28 (36%) | .03 | 14/36 (39%) | .02 | 70/100 (70%) | <.001 |
| ADC restriction | 12/13 (92%) | 3/23 (13%) | <.001 | 4/30 (13%) | <.001 | 35/68 (51%) | .006 |
| IHC features | |||||||
|
OLIG2 positivity |
3/16 (19%) | 29/29 (100%) | <.001 | 36/36 (100%) | .03 | 89/91 (98%) | <.001 |
| Molecular characteristic | |||||||
| IDH mut. | 0/17 (0%) | 0/33 (0%) | .99 | - | - | - | - |
| EGFR amplif. | 2/14 (14%) | 0/33 (0%) | .08 | 2/34 (6%) | .57 | 34/96 (35%) | .13 |
| pTERT mut. | 0/15 (0%) | 2/30 (7%) | .99 | 1/28 (4%) | .99 | 88/100 (88%) | <.001 |
| MGMT meth. | 9/11 (82%) | 4/31 (13%) | .001 | 27/32 (84%) | .99 | 46/93 (49%) | .05 |
| BrafV600E mut. | 0/10 (0%) | 0/30 (0%) | .99 | 0/18 (0%) | .99 | 1/59 (2%) | .99 |
| Median Overall Survival (months) | 12.4 95%CI [6.3–27.5] |
19.6 95%CI [6.1–29.1] |
.56 | 50.5 95% CI [45.9–79.2] |
.006 | 11.7 95%CI [9.3–17.5] |
.45 |
ADC, Apparent diffusion coefficient; CE, Contrast enhancement; SD, Standard deviation.
aH3.3 K27-mutant DMG compared to diffuse hemispheric gliomas, H3 G34-mutant, b IDH-mutant glioblastomas compared to diffuse hemispheric gliomas, H3 G34-mutant, c IDH-wt glioblastomas compared to diffuse hemispheric gliomas, H3 G34-mutant.
Significant P-values are indicated in bold characters.